结肠内喷洒利多卡因对功能性腹痛综合征患者症状的短期影响

注册号:

Registration number:

ChiCTR-IOR-16008187 

最近更新日期:

Date of Last Refreshed on:

2016-03-30 20:11:35 

注册时间:

Date of Registration:

2016-03-30 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

结肠内喷洒利多卡因对功能性腹痛综合征患者症状的短期影响

Public title:

The short-term impact of intracolonic lidocaine spraying on patients with functional abdominal pain syndrome

注册题目简写:

English Acronym:

研究课题的正式科学名称:

结肠内喷洒利多卡因对功能性腹痛综合征患者症状的短期影响

Scientific title:

The short-term impact of intracolonic lidocaine spraying on patients with functional abdominal pain syndrome

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

陈虹霖 

研究负责人:

胡兵 

Applicant:

Chen Honglin 

Study leader:

Hu Bing 

申请注册联系人电话:

Applicant telephone:

+86 18980458220

研究负责人电话:

Study leader's
telephone:

+86 18980601278

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

635636337@qq.com

研究负责人电子邮件:

Study leader's E-mail:

hubingnj@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

成都市武侯区国学巷37号

研究负责人通讯地址:

成都市武侯区国学巷37号

Applicant address:

37 Guoxuexiang, Chengdu, Sichuan, China

Study leader's address:

37 Guoxuexiang, Chengdu, Sichuan, China

申请注册联系人邮政编码:

Applicant postcode:

610041

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

四川大学华西医院消化内科

Applicant's institution:

Department of Gastroenterology, West China Hospital, Sichuan University

研究负责人所在单位:

四川大学华西医院消化内科

Affiliation of the Leader:

Department of Gastroenterology, West China Hospital, Sichuan University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2016-67

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

四川大学华西医院生物医学伦理分委会

Name of the ethic committee:

Biomedical ethics committee of West China Hospital,Sichuan University

伦理委员会批准日期:

Date of approved by ethic committee:

2016-02-22 00:00:00

伦理委员会联系人:

Contact Name of the ethic committee:

伦理委员会联系地址:

Contact Address of the ethic committee:

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

四川大学华西医院消化内科

Primary sponsor:

Department of Gastroenterology, West China Hospital, Sichuan University

研究实施负责(组长)单位地址:

成都市武侯区国学巷37号

Primary sponsor's address:

37 Guoxuexiang, Chengdu, Sichuan, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

四川省

市(区县):

Country:

China

Province:

Sichuan

City:

单位(医院):

四川大学华西医院消化内科

具体地址:

成都市武侯区国学巷37号

Institution
hospital:

Department of Gastroenterology, West China Hospital, Sichuan University

Address:

37 Guoxuexiang, Chengdu, Sichuan, China

经费或物资来源:

Source(s) of funding:

no

研究疾病:

功能性腹痛综合征  

Target disease:

Functional abdominal pain syndrome

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

探索结肠内局部喷洒利多卡因溶液对功能性腹痛综合征患者症状的短期影响  

Objectives of Study:

To study the short-term impact of intracolonic lidocaine spraying on patients with functional abdominal pain syndrome

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1)孕妇及哺乳期妇女,2)有胃肠道或者腹部手术史,3)无痛苦性结肠镜检查发现可致腹痛的器质性病变:炎症性肠病、肠道肿瘤、结肠狭窄、瘘、痔、肛裂、肛周脓肿等,4)有利多卡因使用禁忌症:对利多卡因过敏,肝肾功能障碍,充血性心力衰竭,低血压,心内传导阻滞,预激综合征,肺功能不全等,5)正在服用影响利多卡因代谢的药物且近期不能或不愿停药:西米替丁,β-受体阻滞剂(普萘洛尔,美托洛尔等),巴比妥类药物(硫喷妥钠,苯巴比妥等),硝普钠,甘露醇,磺胺嘧啶银,两性霉素B,氨苄西林等。

Exclusion criteria:

1. Pregnant women and lactating women;
2. Have a history of gastrointestinal or abdominal surgery;
3. painless colonoscopy found pathological changes that can cause abdominal pain: inflammatory bowel disease,intsetinal tumor, stricture of colon, fistula, hemorrhoid,anal fissure, perianal abscess;
4. contraindication of lidocaine: lidocaine allergy,liver and kidney dysfunction,congestive heart-failure, hypotension,cardiac conduction block, Wolff-Parkinson-White syndrome,pulmonary insufficiency;
5. taking drugs that can effect the metabolism of lidocaine,and can not or is not willing to drug withdrawal: Cimetidine, beta-blocker(propranolol, metoprolol), barbiturate(thiopental sodium, phenobarbitone), sodium nitroprusside, mannitol, silvadene, amphotericin B, ampicillin.

研究实施时间:

Study execute time:

From 2016-01-01 00:00:00 To 2016-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2016-04-01 00:00:00 To 2016-09-30 00:00:00

干预措施:

Interventions:

组别:

实验组

样本量:

70

Group:

experimental group

Sample size:

干预措施:

结肠内喷洒利多卡因

干预措施代码:

Intervention:

intracolonic lidocaine spraying

Intervention code:

组别:

对照组

样本量:

70

Group:

control group

Sample size:

干预措施:

结肠内喷洒生理盐水

干预措施代码:

Intervention:

intracolonic saline spraying

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

四川省 

市(区县):

 

Country:

China

Province:

Sichuan

City:

单位(医院):

四川大学华西医院消化内科 

单位级别:

三甲医院 

Institution
hospital:

Department of Gastroenterology, West China Hospital, Sichuan University

Level of the institution:

Tertiary A Hospital

测量指标:

Outcomes:

指标中文名:

腹痛程度

指标类型:

主要指标

Outcome:

Degree of abdominal pain

Type:

Primary indicator

测量时间点:

喷洒液体后1天、3天、一周、两周、一月、三月时

测量方法:

疼痛数值评量表

Measure time point of outcome:

day 1, day 3, week 1, week 2, month 1, month 3, after spraying lidocaine in colon

Measure method:

Pain numerical rating scale

指标中文名:

心率

指标类型:

次要指标

Outcome:

heart rate

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血压

指标类型:

次要指标

Outcome:

bloodpressure

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

动脉血氧分压

指标类型:

次要指标

Outcome:

arterial partial pressure of oxygen

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 70 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

连续纳入符合纳入与排除标准的额140例患者,运用随机数字变将其分成实验组与对照组各70人。

Randomization Procedure (please state who generates the random number sequence and by what method):

consecutively bring into 140 patients that meet the inclusion and exclusion criteria,and devide them into experimental and control group with 70 patients in each group.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

发送邮件到635636337@qq.com,并说明原因后,可了解原始数据。

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Send a e-mail to 635636337@qq.com and explain your reson, you may get a access to the original data.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

每个患者单独建立数据表,详细记录基本信息,每次随访时患者的腹痛情况。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Each patient has his individual form to record his essential information and degree of abdominal pain during the follow-up period.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

注册人:

Name of Registration:

 2016-03-30 20:11:35